Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism.

Clinica chimica acta; international journal of clinical chemistry - 1 May 2006

Lee Hong-Kee, Lewis Lionel D, Tsongalis Gregory J, McMullin Matthew, Schur Bernard C, Wong Steven H, Yeo Kiang-Teck J

Abstract excerpt

INTRODUCTION: Oxycodone has become widely used in the clinic for the treatment of chronic pain. This reflects its favorable pharmacokinetics and side effect profiles. CASE REPORT: We report a 60-y-old man who had a clinically significant drug interaction between rifampin and oxycodone, resulting in 3 consecutive negative urine oxycodone screens in a 2-month period, suggesting non-adherence. A combination of urine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Gas Chromatography-Mass Spectrometry

Share to Molecular Structure

Share to Narcotics

Share to Rifampin

Source

Identifiers

PMID: 16414038
DOI: 10.1016/j.cca.2005.11.030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism.PMID 16414038Read ↗

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

Rapid Methadone Metabolism in Opioid Use Disorder: A Case Report of Clinical Challenges and Individualized Treatment ApproachesSemantic proximity Read ↗

Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests.Semantic proximity Read ↗

Role of CYP3A5 in abnormal clearance of methadone.Semantic proximity Read ↗

Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort.Semantic proximity Read ↗

Analysis of electronic health records reveals medication-related interference on point-of-care urine drug screening assaysSemantic proximity Read ↗

CYP450-based reclassification of urinary metabolic ratio cutoffs for pain management and substance abuse treatment drugs.Semantic proximity Read ↗

Toward precision prescribing for methadone: Determinants of methadone deposition.Semantic proximity Read ↗

Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.Semantic proximity Read ↗

Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.Semantic proximity Read ↗

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.